Skip to main content
. 2018 Nov 29;18:1185. doi: 10.1186/s12885-018-5101-3

Fig. 3.

Fig. 3

Survival estimate of patients with metastatic pancreatic cancer starting combined treatment with nab-paclitaxel plus gemcitabine in real-life practice. a Nomogram for predicting overall survival and the probability of 3-month, 6-month, 12-month in real-life practice. b Survival (Kaplan Meier estimate) for low-, medium-, and high-risk groups